

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>*Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents</p> <p>Members 3–17 years of age, who had an outpatient visit with a PCP or OB/GYN during the measurement year (2024) and had evidence of the following documented:</p> <ul style="list-style-type: none"> BMI percentile* counseling for nutrition counseling for physical activity <p>ICD-10 Codes:</p> <p>BMI percentile: Z68.51–Z68.54 Counseling for nutrition: Z71.3 Counseling for physical activity: Z02.5, Z71.82</p> <p>CPT Codes:</p> <p>Counseling for nutrition: 97802–97804</p> <p><i>* Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value.</i></p>	<p>BMI Percentile documentation must include date, height, weight and:</p> <ul style="list-style-type: none"> BMI percentile may be plotted on age-growth chart. Weight and height must be taken during the measurement year (2024). <p>Counseling for nutrition documentation must include a note indicating the date and at least one of the following:</p> <ul style="list-style-type: none"> discussion of current nutrition behaviors (e.g., eating habits, dieting behaviors) checklist indicating nutrition was addressed counseling or referral for nutrition education educational materials on nutrition during a face-to-face visit anticipatory guidance for nutrition weight or obesity counseling referral to WIC <p>Counseling for physical activity documentation must include a note indicating the date and at least one of the following:</p> <ul style="list-style-type: none"> discussion of current physical activity behaviors (e.g., exercise routine, participation in sports activities, exam for sports participation) checklist indicating physical activity was addressed counseling or referral for physical activity educational materials on physical activity during a face-to-face visit anticipatory guidance specific to the child’s physical activity weight or obesity counseling <p>Documentation of meeting Developmental Milestones only does not meet HEDIS® criteria for physical activity counseling.</p> <p>Services specific to an acute or chronic condition do not count toward the counseling indicators for either nutrition or physical activity.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year. members who have a diagnosis of pregnancy anytime during the measurement year. members who died anytime during the measurement year.

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>*Childhood Immunization</p> <p>Children who turn 2 years old during the measurement year (2024)</p> <p>Vaccines must be completed on or before the second birthday.</p> <p>CPT Codes:</p> <p>Dtap: 90697, 90698, 90700, 90723</p> <p>IPV: 90697, 90698, 90713, 90723</p> <p>HiB: 90644, 90647, 90648, 90697, 90698, 90748</p> <p>Pneumococcal Conjugate: 90670, 90671</p> <p>Rotavirus (2 dose): 90681</p> <p>Rotavirus (3 dose): 90680</p> <p>VZV: 90710, 90716</p> <p>MMR: 90707; 90710</p> <p>Hepatitis A: 90633</p> <p>Hepatitis B: 90697, 90723, 90740, 90744, 90747, 90748</p> <p>Influenza: 90655, 90657, 90661, 90673, 90674, 90685, 90686, 90687, 90688, 90689, 90765</p> <p>LAIV: 90660, 90672</p>	<ul style="list-style-type: none"> • 4 DTaP or anaphylaxis or encephalitis due to diphtheria, tetanus, or pertussis vaccine (do not count any before 42 days of age) • 3 IPV or anaphylaxis due to the IPV vaccine (do not count any before 42 days of age) • 1 MMR; history of measles, mumps, and rubella; or anaphylaxis due to the MMR vaccine (do not count any before 42 days of age) • 3 HiB or anaphylaxis due to HiB vaccine (do not count any before 42 days of age) • 3 hepatitis B, anaphylaxis due to hepatitis B vaccine, positive serology, or history of hepatitis B • 1 VZV, anaphylaxis due to the VZV vaccine, positive serology, or documented history of chicken pox disease • 4 pneumococcal conjugates or anaphylaxis due to the pneumococcal conjugate vaccine (do not count any before 42 days of age) • 1 hepatitis A, anaphylaxis due to the hepatitis A vaccine, or documented hepatitis A illness • 2 or 3 rotavirus vaccines – depends on the vaccine administered or documented anaphylaxis due to the rotavirus vaccine (do not count any before 42 days of age) • 2 influenza with different dates of service or anaphylaxis due to the influenza vaccine – One of the two vaccinations can be a live attenuated influenza vaccine (LAIV) if administered on the child's second birthday (do not count any given prior to 6 months of age). <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year. • members who had a contraindication to a childhood vaccine on or before their second birthday. • members who died anytime during the measurement year. <p>Parental refusal is <i>not</i> an exclusion.</p> <p>Documentation of "immunizations are up-to-date" is not acceptable.</p> <p>Documentation of an immunization (such as the first hep B) received "at delivery" or "in the hospital" may be counted.</p> <p>For documented history of illness, a seropositive test result, or anaphylaxis, there must be a note indicating the date of the event, which must have occurred by the the member's second birthday.</p>

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>*Immunizations for Adolescents</p> <p>Children who turn 13 years old during the measurement year (2024).</p> <p>CPT Codes:</p> <p>Meningococcal CPT: 90619, 90733, 90734</p> <p>Tdap: 90715</p> <p>HPV: 90649–90651</p> <p><i>Note: This measure includes the human papillomavirus vaccine (HPV) for both males and females.</i></p>	<ul style="list-style-type: none"> 1 dose meningococcal vaccine between the 11th and 13th birthdays or anaphylaxis due to the vaccine anytime on or before the member's 13th birthday and 1 tetanus, diphtheria toxoids, and acellular pertussis (Tdap) vaccine between the 10th and 13th birthdays or anaphylaxis or encephalitis due to the vaccine anytime on or before the 13th birthday and 2-dose or 3-dose HPV vaccination series between the 9th and 13th birthdays or anaphylaxis due to the vaccine anytime on or before the 13th birthday <p>All vaccines must be completed on or before the 13th birthday.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year. members who died anytime during the measurement year. <p>Parental refusal is not an exclusion.</p> <p>Documentation of "immunizations are up-to-date" is not acceptable. For meningococcal, do not count meningococcal recombinant (serogroup B) (MenB) vaccines.</p> <p>For documented history of anaphylaxis, there must be a note indicating the date of the event, which must have occurred by the member's 13th birthday.</p>
<p>*Lead Screening in Children (Medicaid only)</p> <p>Children who turn 2 years old during the measurement year (2024).</p> <p>CPT Code: 83655</p>	<p>At least one capillary or venous lead blood test by their second birthday</p> <p>Documentation in the record must include both of the following:</p> <ul style="list-style-type: none"> date the test was performed the result or finding <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year. members who died anytime during the measurement year.

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>*Cervical Cancer Screening (CCS)</p> <p>Members ages 21–64</p> <p>CPT Codes to identify cervical cancer screening cervical cytology: 88141–88143, 88147–88148, 88150, 88152, 88153, 88164–88167, 88174–88175</p> <p>CPT Codes to identify HPV tests: 87624–87625</p> <p><i>Note: Evidence of hrHPV testing within the last five years also captures patients who had cotesting; therefore, additional methods to identify cotesting are not necessary.</i></p>	<ul style="list-style-type: none"> a PAP test (cervical cytology) within the last three years (2022–2024) for members ages 21–64 cervical high-risk human papillomavirus (hrHPV) testing within the last five years (2020–2024) for members ages 30–64 cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last five years (2020–2024) for members ages 30–64. <p>Documentation in the record must include both of the following:</p> <ul style="list-style-type: none"> date the test was performed the result or finding <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services or receiving palliative care anytime during the measurement year documentation of hysterectomy with no residual cervix, cervical agenesis, or acquired absence of cervix members who died during the measurement year members with sex assigned at birth of male at any time in the patient’s history
<p>Care for Older Adults (COA) *Medicare</p> <p>Adults 66 years of age and older</p> <p>CPT Codes for COA:</p> <p>Medication Review: 1160F, 90863, 99483, 99605, 99606</p> <p>Medication List: 1159F</p> <p>Transition Care Management: 99495, 99496</p> <p>Functional Status Assessment: 1170F, 99483</p> <p>Pain Assessment: 1125F, 1126F</p>	<p>Members who had each of the following during the measurement year (2024):</p> <ul style="list-style-type: none"> medication review – a review of all a member’s medications, including prescription medications, OTC medications, and herbal or supplemental therapies functional status assessment – a complete functional assessment and the date when it was performed pain assessment – notation of a pain assessment and the date it was performed. <p>Do not include pain assessments performed in an acute inpatient setting. The functional status assessment and pain assessment indicators do not require a specific setting; therefore, services rendered during telephone visit, e-visit, or virtual check-in meet criteria. Notation alone of a pain management or treatment plan does not meet criteria.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> Members in hospice or using hospice services anytime during the measurement year. Members who died anytime during the measurement year.

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Oral Evaluation, Dental Services (OED)</p> <p>Members under 21 years of age</p> <p><i>*This measure has been included in and/or adapted for HEDIS with the permission of the Dental Quality Alliance (DQA) and American Dental Association (ADA). © 2023 DQA on behalf of ADA, all rights reserved.</i></p>	<p>Members who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year (2024).</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>Topical Fluoride for Children (TFC)</p> <p>Members 1–4 years of age</p> <p><i>* This measure has been included in and/or adapted for HEDIS with the permission of the Dental Quality Alliance (DQA) and American Dental Association (ADA). © 2023 DQA on behalf of ADA, all rights reserved.</i></p>	<p>Members who received at least two fluoride varnish applications during the measurement year (2024):</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Appropriate Testing for Pharyngitis (CWP)</p> <p>Ages 3 years and older</p> <p>ICD-10 Codes To Identify Pharyngitis: J02.0, J02.8–J02.9, J03.00–J03.01, J03.80–J03.81, J03.90–J03.91</p>	<ul style="list-style-type: none"> • diagnosis of pharyngitis • prescribed an antibiotic <p style="text-align: center;">and</p> <ul style="list-style-type: none"> • received a group A streptococcus (strep) test for the episode <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Pharmacotherapy Management of COPD Exacerbation (PCE)</p> <p>Adults 40 years and older</p> <p>ICD-10 Codes To Identify COPD: J44.0, J44.1, J44.9</p>	<ul style="list-style-type: none"> • discharged from an acute inpatient admission or an ED visit with a primary diagnosis of COPD on or between January 1–November 30, 2024 <p style="text-align: center;">and</p> <ul style="list-style-type: none"> • prescribed appropriate medications (or already had an active prescription for): <ul style="list-style-type: none"> • a systemic corticosteroid within 14 days of the event • a bronchodilator within 30 days of the event <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Asthma Medication Ratio (AMR)</p> <p>Ages 5–64</p> <p>ICD10 Codes To Identify Asthma: J45.21, J45.22, J45.30, J45.31, J45.32, J45.40, J45.41, J45.42, J45.50, J45.51, J45.52, J45.901, J45.902, J45.909, J45.991, J45.998</p>	<p>Members identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year (2024)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> • members who had any diagnosis of the following during the member's history through December 31 of the measurement year: emphysema, COPD, obstructive chronic bronchitis, chronic respiratory condition due to fumes or vapors, cystic fibrosis, or acute respiratory failure. • members who had no asthma controller or reliever medications prescribed during the measurement year. • members in hospice or using hospice services any time during the measurement year. • members who died any time during the measurement year.

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>*Controlling High Blood Pressure (CBP) Adults ages 18–85 <i>Adequate control</i> is defined as: <140/90 ICD-10 Codes To Identify HTN: I10 CPT II Codes for BP values: Systolic less than 140: 3074F, 3075F Systolic greater than/equal to 140: 3077F Diastolic less than 80: 3078F Diastolic 80–89: 3079F Diastolic greater than/equal to 90: 3080F</p>	<ul style="list-style-type: none"> • diagnosis of hypertension (HTN) • most recent blood pressure reading in the medical record for 2024 <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services or receiving palliative care anytime during the measurement year • members with evidence of end-stage renal disease (ESRD), dialysis, nephrectomy, or kidney transplant anytime during the member’s history on or prior to December 31 of the measurement year • members with a diagnosis of pregnancy anytime during the measurement year • members who died any time during the measurement year
<p>Cardiac Rehabilitation (CRE) Adults 18 years and older CPT codes: 93797–93798</p>	<p>Members who attended cardiac rehabilitation following a qualifying cardiac event (myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation, or heart valve repair/replacement)</p> <p>Four rates are reported:</p> <ol style="list-style-type: none"> 1. Initiation: percentage of members who attended two or more sessions of cardiac rehabilitation within 30 days after a qualifying event 2. Engagement 1: percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event 3. Engagement 2: percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event 4. Achievement: percentage of members who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event <p>Exclude members who meet any of the following criteria:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services or receiving palliative care any time during the measurement year • members who died any time during the measurement year • discharged from an inpatient setting with any of the following on the discharge 180 days after the episode date: MI, CABG, heart or heart/lung transplant, or heart valve repair or replacement

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)
 For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Statin Therapy for Patients With Cardiovascular Disease (SPC)</p> <p>Males ages 21–75; Females ages 40–75</p> <p>Moderate or High-intensity Statin Therapy:</p> <p>Atorvastatin: 10–80mg Amlodipine-atorvastatin: 10–80mg Rosuvastatin: 5–40mg Simvastatin: 20–80mg Ezetimibe-simvastatin: 20–80mg Pravastatin: 40–80mg Lovastatin: 40mg Fluvastatin 40–80mg Pitavastatin 1–4mg</p> <p>ICD-10 Codes for Myalgia/Myositis/Myopathy/Rhabdomyolysis:</p> <p>G72.0, G72.2, G72.9, M60.80–M60.812, M60.819, M60.821–M60.822, M60.829, M60.831–M60.832, M60.839, M60.841–M60.842, M60.849, M60.851–M60.852, M60.859, M60.861–M60.862, M60.869, M60.871–M60.872, M60.879, M60.88–M60.89, M60.9, M62.82, M79.1–M79.12, M79.18</p>	<p>Identified as having clinical atherosclerotic cardiovascular disease (ASCVD) during the measurement year (2024)</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> Received Statin Therapy: members who were dispensed at least one high or moderate-intensity statin medication during the measurement year Statin Adherence 80%: members who remained on a high or moderate-intensity statin medication for at least 80% of the treatment period (from prescription date through end of year) <p>Exclude members who meet any of the following criteria:</p> <ul style="list-style-type: none"> diagnosis of pregnancy or had IVF during the measurement year or the year prior diagnosis of ESRD, dialysis, or cirrhosis during the measurement year or the year prior diagnosis of myalgia, myositis, myopathy, or rhabdomyolysis during the measurement year dispensed at least one prescription for clomiphene during the measurement year or the year prior in hospice or using hospice services or receiving palliative care any time during the measurement year members who died any time during the measurement year

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Glycemic Status Assessment for Patients With Diabetes (GSD)</p> <p>Adults 18–75 years</p> <p>ICD-10 Codes To Identify Diabetes: E10.10, E10.11, E10.21, E10.22, E10.29, E11.00–E11.9, E13.00–E13.9</p> <p>CPT/CPT II for HbA1c: 83036, 83037, 3044F, 3046F, 3051F, 3052F</p>	<p>Diagnosis of diabetes (Types 1 and 2) whose most recent glycemic status (hemoglobin A1c (HbA1c) or glucose management indicator (GMI) was at the following levels from measurement year (2024):</p> <ul style="list-style-type: none"> • Glycemic Status (<8.0%) • Glycemic Status (>9.0%) <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice, using hospice services or palliative care anytime during the measurement year • members who died anytime during the measurement year
<p>Blood Pressure Control for Patients With Diabetes (BPD)</p> <p>Adults 18–75 years</p> <p>ICD-10 Codes To Identify Diabetes: E10.10, E10.11, E10.21, E10.22, E10.29, E11.00–E11.9, E13.00–E13.9</p> <p>CPT/CPT II Codes for BP values:</p> <p>Systolic less than 140: 3074F, 3075F</p> <p>Systolic greater than/equal to 140: 3077F</p> <p>Diastolic less than 80: 3078F</p> <p>Diastolic 80–89: 3079F</p> <p>Diastolic greater than/equal to 90: 3080F</p>	<p>Diagnosis of diabetes (Types 1 and 2) whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement year (2024).</p> <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice, using hospice services or receiving palliative care any time during the measurement year • members who died any time during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Eye Exam for Patients With Diabetes (EED) Adults 18–75 years</p> <p>ICD-10 Codes To Identify Diabetes: E10.10, E10.11, E10.21, E10.22, E10.29, E11.00–E11.9, E13.00–E13.9</p> <p>CPT/CPT II codes for Diabetic Retinal Screening: 67028, 67030, 67031, 67036, 67039–67043, 67101, 67105, 67107, 67108, 67110, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92201, 92202, 92227, 92228, 92230, 92235, 92240, 92250, 92260, 99203–92205, 99213–99215, 99242–99245, 2022F–2026F, 2033F, 3072F</p>	<p>Diagnosis of diabetes (Types 1 and 2) who had one of the following:</p> <ul style="list-style-type: none"> a retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in 2024 a negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional (optometrist or ophthalmologist) in 2023 <p style="text-align: center;">or</p> <ul style="list-style-type: none"> bilateral eye enucleation anytime during the member’s history through December 31 of the measurement year <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice, using hospice services, or receiving palliative care anytime during the measurement year members who died anytime during the measurement year
<p>*Kidney Health Evaluation for Patients With Diabetes Adults ages 18–85</p> <p>ICD-10 Codes To Identify Diabetes: E10.10, E10.11, E10.21, E10.22, E10.29, E11.00–E11.9, E13.00–E13.9</p> <p>CPT Codes: eGFR: 80047–80048, 80050, 80053, 80069, 82565 uACR: 82043, 82570</p> <p><small>*This measure was developed by NCQA with input from the National Kidney Foundation.</small></p>	<p>Diagnosis of diabetes (Type 1 and Type 2) who received a kidney health evaluation during the measurement year (2024), defined by:</p> <ul style="list-style-type: none"> an estimated glomerular filtration rate (eGFR) <p style="text-align: center;">and</p> <ul style="list-style-type: none"> a urine albumin-creatinine ratio (uACR) <p>Exclusions:</p> <ul style="list-style-type: none"> members with evidence of ESRD or dialysis anytime during the member’s history on or prior to December 31 of the measurement year members in hospice or using hospice services or receiving palliative care anytime during the measurement year members who died anytime during the measurement year

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)
For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Statin Therapy for Patients With Diabetes (SPD) Adults ages 40–75</p> <p>ICD-10 Codes for Myalgia/Myositis/Myopathy/Rhabdomyolysis: G72.0, G72.2, G72.9, M60.80–M60.812, M60.819, M60.821–M60.822, M60.829, M60.831–M60.832, M60.839, M60.841–M60.842, M60.849, M60.851–M60.852, M60.859, M60.861–M60.862, M60.869, M60.871–M60.872, M60.879, M60.88-60.89, M60.9, M62.82, M79.11-M79.12, M79.18</p>	<p>Identified as having diabetes but do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria:</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. Received Statin Therapy: members who were dispensed at least one statin medication of any intensity during the measurement year (2024) 2. Statin Adherence 80%: members who remained on a statin medication of any intensity for at least 80% of the treatment period (from prescription date through end of year) <p>Exclusions:</p> <ul style="list-style-type: none"> members diagnosed with myalgia, myositis, myopathy, or rhabdomyolysis (in 2024) members with any of the following (in 2023 or 2024): IVD diagnosis, pregnancy/IVF, prescribed clomiphene, ESRD or dialysis, cirrhosis members who had at least one of the following during the year prior to the measurement year: discharged from an inpatient setting with MI or had a CABG, PCI, or other revascularization procedure members in hospice or using hospice services or receiving palliative care anytime during the measurement year members who died any time during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Osteoporosis Management in Women Who Had a Fracture (OMW) *Medicare Women ages 67–85</p> <p>CPT Codes To Identify BMD Test: 76977, 77078, 77080–77081, 77085–77086</p> <p>HCPCS Codes for Osteoporosis Meds: J0897, J1740, J3110, J3489</p>	<p>Suffered a fracture and had one of the following in the six months after the fracture:</p> <ul style="list-style-type: none"> • a bone mineral density (BMD) test <p style="text-align: center;">or</p> <ul style="list-style-type: none"> • a prescription for a drug to treat osteoporosis <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who received palliative care anytime during the intake period through the end of the measurement year • members who died anytime during the measurement year
<p>Osteoporosis Screening in Older Women (OSW) *Medicare Women ages 65–75</p> <p>CPT Codes: 76977, 77078, 77080–77081, 77085</p>	<p>Received one or more osteoporosis screening tests on or between the member's 65th birthday and December 31 of the measurement year (2024)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> • members who had a claim/encounter for osteoporosis therapy any time in the member's history through December 31 of the year prior to the measurement year • members who were prescribed a prescription to treat osteoporosis any time on or between January 1, 2021, through December 31, 2023 • members in hospice or using hospice services or receiving palliative care anytime during the measurement year • members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)
For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Antidepressant Medication Management (AMM) Adult ages 18 and older ICD-10 Codes To Identify Major Depression: F32.0, F32.1, F32.2, F32.3 F32.4, F32.9, F33.0, F33.1, F33.2, F33.3, F33.41, F33.9</p>	<p>Members treated with antidepressant medication who had a diagnosis of major depression and remained on antidepressant medication treatment</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. Effective Acute Phase Treatment – the percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks) 2. Effective Continuation Phase Treatment – the percentage of members who remained on an antidepressant medication for at least 180 days (6 months) <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Follow-up After Hospitalization for Mental Illness (FUH) Ages 6 and over</p>	<ul style="list-style-type: none"> • hospitalized for treatment of selected mental illness or intentional self-harm and • one follow-up outpatient visit, intensive outpatient encounter, or partial hospitalization with a mental health provider <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. follow-up visit within seven days of discharge 2. follow-up visit within 30 days of discharge <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Follow-up After Emergency Department Visit for Mental Illness (FUM)* Ages 6 years and older</p> <p><small>*Adapted from an NCQA measure with financial support from the Office of the Assistant Secretary for Planning and Evaluation (ASPE) under Prime Contract No. HHSP23320100019WI/HHSP23337001T, in which NCQA was a subcontractor to Mathematica. Additional financial support was provided by the Substance Abuse and Mental Health Services Administration (SAMHSA).</small></p>	<p>Diagnosed with a mental illness or intentional self-harm, who had a follow-up visit for mental illness.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. the percentage of ED visits for which the member received follow-up within seven days of the ED visit (eight total days) 2. the percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days) <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Follow-up After High-intensity Care for Substance Use Disorder (FUI)</p> <p>Ages 13 and older</p>	<ul style="list-style-type: none"> • acute inpatient hospitalization, residential treatment, or detoxification visit • diagnosis of substance use disorder • follow-up visit or event with any practitioner for a principal diagnosis of substance use disorder <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. the percentage of visits or discharges for which members received follow-up for substance use disorder within seven days after the visit or discharge 2. the percentage of visits or discharges for which members received follow-up for substance use disorder within 30 days after the visit or discharge <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Follow-up After Emergency Department Visit for Substance Use (FUA)</p> <p>Ages 13 and older</p>	<p>ED visit with principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was a follow-up.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. follow-up visit within seven days of the ED visit (eight total days) 2. follow-up visit within 30 days of the ED visit (31 total days) <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Pharmacotherapy for Opioid Use Disorder (POD)</p> <p>Ages 16 and older</p>	<ul style="list-style-type: none"> • diagnosis of opioid use disorder • dispensed an opioid use disorder treatment medication (e.g., Naltrexone, Buprenorphine) taken for 180 days or more without a gap in treatment of eight or more consecutive days. <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)</p> <p>Adults ages 18–64</p> <p>ICD-10 Codes To Identify Diagnosis:</p> <p>Bipolar: F30.10–F30.13, F30.2–F30.4, F30.8–F30.9, F31.0, F31.10–F31.13, F31.2, F31.30–F31.32, F31.4–F31.5, F31.60–F31.64, F31.70–F31.78, F31.81, F31.89, F31.9</p> <p>Schizophrenia: F20.0–F20.3, F20.5, F20.81, F20.89, F20.9, F25.0–F25.1, F25.8–F25.9</p> <p>CPT Codes To Identify Diabetes Screening:</p> <p>Glucose tests: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951</p> <p>HbA1c tests: 83036, 83037</p>	<ul style="list-style-type: none"> • diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder • dispensed an antipsychotic medication on an ambulatory basis • diabetes screening (glucose or HbA1c) test during the measurement year (2024) <p>Exclusions:</p> <ul style="list-style-type: none"> • members with diabetes or who were dispensed insulin or oral hypoglycemics/ antihyperglycemics during the measurement year or the year prior to the measurement year • members who had no antipsychotic medications dispensed during the measurement year • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)</p> <p>Adults ages 18–64</p> <p>CPT Codes To Identify:</p> <p>HbA1c tests: 83036, 83037</p> <p>LDL-C Screening: 80061, 83700, 83701, 83704, 83721</p>	<p>Members with a diagnosis of schizophrenia or schizoaffective disorder and diabetes who had both an LCL-C test and an HbA1c test during the measurement year (2024)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)*</p> <p>Adults 18 and older</p> <p><i>*Adapted by NCQA with permission of the measure developer, CMS.</i></p>	<p>Diagnosis of schizophrenia or schizoaffective disorder who were prescribed and remained on an antipsychotic medication for at least 80% of their treatment period (days between the earliest prescription fill in 2024 and the end of the year.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> • a diagnosis of dementia • <i>did not</i> have at least two antipsychotic medication dispensing events • members in hospice or using hospice services during the measurement year • members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)
For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Advance Care Planning (ACP) *Medicare</p> <p>Adults ages 66–80 with advanced illness, an indication of frailty, or receiving palliative care; and adults ages 81 years and older who had advanced care planning during the measurement year (2024)</p> <p>CPT Codes To Identify Advance Care Planning: 99483, 99497</p>	<p>Advance Care Planning is the discussion or documentation about preferences for resuscitation, life-sustaining treatment, or end-of-life care.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>Transitions of Care (TRC) *Medicare</p> <p>Adults ages 18 and older</p> <p>CPT codes for Transitional Care Management Services and Medication Reconciliation: 99483, 99495, 99496, 1111F</p>	<p>Documentation in the PCP record of the following in 2024:</p> <ul style="list-style-type: none"> Notification of Inpatient Admission on the day of admission through two days after Receipt of Discharge Information on the day of discharge through two days after Patient Engagement After Inpatient Discharge (e.g., office visits, home visits, telehealth) provided within 30 days after discharge Medication Reconciliation Post-discharge conducted by a prescribing practitioner, clinical pharmacist, physician assistant, or registered nurse on the date of discharge through 30 days after discharge (documentation of review of <i>both</i> a list of the member’s current outpatient medications and the discharge medications, or notation that no medications were prescribed upon discharge) <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services during the measurement year members who died during the measurement year
<p>Follow-up After Emergency Department Visit for People With Multiple High-risk Chronic Conditions (FMC) *Medicare</p> <p>Ages 18 and older</p>	<p>Members with Emergency Department (ED) visits who have multiple (two or more) high-risk chronic conditions, such as COPD/asthma; dementia; CKD; major depression; heart failure; MI; atrial fibrillation; or stroke, who had a follow-up service within seven days of the ED visit (eight total days)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Nonrecommended PSA-based Screening in Older Men (PSA) *Medicare</p> <p>Men age 70 and older</p> <p>CPT codes for PSA-based Screening:</p> <p>84152–84154</p>	<p>Screened unnecessarily for prostate cancer using prostate-specific antigen (PSA)-based screening during the measurement year (2024)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> prostate cancer diagnosis anytime during the member’s history through December 31 of the measurement year dysplasia of the prostate anytime during the measurement year or the year prior to the measurement year a PSA test during the year <i>prior to</i> the measurement year (2023) where laboratory data indicate an elevated (>4.0 ng/ml) or abnormal result dispensed prescription for a 5-alpha reductase inhibitor during the measurement year members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>Appropriate Treatment for Upper Respiratory Infection (URI)</p> <p>Ages 3 months and older</p>	<p>Members with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic-dispensing event</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)</p> <p>Ages 3 months and older</p> <p>ICD-10 Codes To Identify Acute Bronchitis:</p> <p>J20.3–J20.9, J21.0–J21.1, J21.8–J21.9</p>	<p>Diagnosis of acute bronchitis/bronchiolitis and not prescribed an antibiotic</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members with a diagnosis of any of the following comorbid conditions: emphysema, COPD, immune system disorder, HIV, malignant neoplasms members who died anytime during the measurement year

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Use of Imaging Studies for Low Back Pain (LBP)</p> <p>Adults ages 18–75</p> <p>ICD-10 Codes To Identify Uncomplicated Low Back Pain:</p> <p>M47.26–M47.28, M47.816–M47.818, M47.896–M47.898, M48.061–M48.07, M48.08, M51.16–M51.17, M51.26, M51.27–M51.36, M51.37, M51.86, M51.87, M53.2X6–M53.2X8–M53.88, M54.16–M54.9, M99.03–M99.84 S33.100A–S33.9XXA, S39.002A–S39.92XS</p> <p><i>Note: A higher score indicates appropriate treatment of low back pain.</i></p>	<p>Principal diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services or receiving palliative care anytime during the measurement year members who died anytime during the measurement year diagnosis of cancer, HIV, spondylopathy, major organ transplant, or history of major organ transplant, osteoporosis therapy, or a dispensed prescription to treat osteoporosis or lumbar surgery anytime during the member's history through 28 days after the IESD trauma or a fragility fracture anytime during the 90 days prior to the IESD through 28 days after the IESD IV drug abuse, neurological impairment, or spinal infection anytime during the 365 days prior to IESD through 28 days after IESD prolonged use of corticosteroids: 90 consecutive days of corticosteroid treatment anytime during the 365 days prior to the IESD and ends on the IESD <p>Index Episode Start Date (IESD) is defined as the earliest date of service for an eligible encounter during the intake period (January 1 through December 3, 2024) with a principal diagnosis of low back pain.</p>
<p>Potentially Harmful Drug-Disease Interactions in Older Adults (DDE) *Medicare</p> <p>Ages 65 and older</p> <p><i>Note: A lower rate represents better performance for all rates.</i></p>	<p>Evidence of an underlying disease, condition, or health concern and who were dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis</p> <p>Three rates are reported:</p> <ol style="list-style-type: none"> a history of falls and a prescription for antiepileptics, antipsychotics, benzodiazepines, non-benzodiazepine hypnotics, or antidepressants (SSRIs, tricyclic antidepressants, SNRIs) dementia and a prescription for antipsychotics, benzodiazepines, non-benzodiazepine hypnotics, tricyclic antidepressants, or anticholinergic agents chronic kidney disease and a prescription for Cox-2 selective NSAIDs or non-aspirin NSAIDs <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services or receiving palliative care anytime during the measurement year members with a diagnosis of psychosis, schizophrenia, schizoaffective disorder, or bipolar disorder on or between January 1, 2023, and December 1, 2024 members who died anytime during the measurement year

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Use of High-risk Medications in Older Adults (DAE) *Medicare</p> <p>Ages 67 and older</p> <p><i>Note: a lower rate represents a better performance.</i></p>	<p>Received at least two dispensing events for high-risk medications to avoid from the same drug class (except for appropriate diagnoses)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members receiving palliative care during the measurement year members who died anytime during the measurement year
<p>Deprescribing of Benzodiazepines in Older Adults (DBO) *Medicare</p> <p>Adults 67 years of age and older</p> <p><i>Note: A lower rate represents better performance for all rates.</i></p>	<p>Members who were dispensed benzodiazepines and experienced a 20% decrease or greater in benzodiazepine dose (diazepam milligram equivalent [DME] dose) during the measurement year (2024)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members with a diagnosis of seizure disorder, REM sleep behavior disorder, benzodiazepine withdrawal, or ethanol withdrawal on or before January 1 of the year prior to the measurement year and the ITE start date members in hospice or using hospice services or receiving palliative care members who died anytime during the measurement year
<p>Use of Opioids at High Dosage (HDO)</p> <p>Adults ages 18 and older</p> <p><i>Note: A lower rate indicates better performance.</i></p>	<p>Received a prescription for opioids at a high dosage (average morphine milligram equivalent dose [MME] ≥ 90) for ≥ 15 days during the measurement year (2024)</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members with cancer or sickle cell disease anytime during the measurement year members in hospice or using hospice services or receiving palliative care anytime during the measurement year members who died anytime during the measurement year

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Use of Opioids From Multiple Providers (UOP)</p> <p>Ages 18 and older</p> <p><i>Note: A lower rate indicates better performance.</i></p>	<p>Received prescription opioids for ≥ 15 days from multiple providers during the measurement year (2024)</p> <p>Three rates are reported: Opioid prescriptions received from and/or filled at:</p> <ol style="list-style-type: none"> 1. Multiple Prescribers (four or more different prescribers) 2. Multiple Pharmacies (four or more different pharmacies) 3. Multiple Prescribers and Multiple Pharmacies (both four or more different prescribers and four or more different pharmacies) <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year. • members who died any time during the measurement year.
<p>Risk of Continued Opioid Use (COU)</p> <p>Ages 18 and older</p>	<p>A new episode of opioid use that puts them at risk for continued opioid use</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. the percentage of members with at least 15 days of prescription opioids in a 30-day period 2. the percentage of members with at least 31 days of prescription opioids in a 62-day period <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who had at least one of the following during the 12 months (1 year) prior to the prescription start date through 61 days after the prescription start date: cancer, sickle cell disease, or palliative care • members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through the Medicare Health Outcomes Survey

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Fall Risk Management (FRM) *Medicare</p> <p>Adults ages 65 and older</p>	<p>Two components of this measure that assess different facets of fall risk management:</p> <ol style="list-style-type: none"> 1. discussing fall risk <ul style="list-style-type: none"> • seen by a practitioner in the past 12 months • discussed falls or problems with balance or walking with their current practitioner 2. managing fall risk <ul style="list-style-type: none"> • had a fall or problems with balance or walking in the past 12 months • seen by a practitioner in the past 12 months • received a recommendation for how to prevent falls or treat problems with balance or walking from their current practitioner
<p>Management of Urinary Incontinence in Older Adults (MUI) *Medicare</p> <p>Adults ages 65 and older</p>	<p>Three components that assess the management of urinary incontinence in older adults:</p> <ol style="list-style-type: none"> 1. discussing urinary incontinence <ul style="list-style-type: none"> • reported having urine leakage in the past 6 months • discussed their urinary leakage problem with a healthcare provider 2. discussing treatment of urinary incontinence <ul style="list-style-type: none"> • reported having urine leakage in the past 6 months • discussed treatment options for their current urine leakage problem 3. impact of urinary incontinence <ul style="list-style-type: none"> • reported having urine leakage in the past 6 months • reported that urine leakage made them change their daily activities or interfered with their sleep a lot
<p>Physical Activity in Older Adults (PAO) *Medicare</p> <p>Adults ages 65 and older</p>	<p>Two components of this measure that assess different facets of promoting physical activity in older adults:</p> <ol style="list-style-type: none"> 1. discussing physical activity <ul style="list-style-type: none"> • had a doctor’s visit in the past 12 months • spoke with a doctor or other healthcare provider about their level of exercise or physical activity 2. advising physical activity <ul style="list-style-type: none"> • had a doctor’s visit in the past 12 months • received advice to start, increase, or maintain their level of exercise or physical activity

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through the Medicare Health Outcomes Survey

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Medical Assistance With Smoking Cessation and Tobacco Use Cessation (MSC)</p> <p>Current smoker/tobacco user ages 18 and older</p>	<p>This measure assesses three different components of providing medical assistance with smoking and tobacco use cessation:</p> <ol style="list-style-type: none"> 1. advising smokers and tobacco users to quit – received advice to quit during the measurement year (2024) 2. discussing cessation medications – discussed or were recommended cessation medications during the measurement year (2024) 3. discussing cessation strategies <p>Discussed or were provided cessation methods or strategies during the measurement year (2024)</p>

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)
For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Adults' Access to Preventive/Ambulatory Health Services (AAP)</p> <p>Adults ages 20 and over</p>	<p>An ambulatory or preventive care visit</p> <ul style="list-style-type: none"> in the measurement year (2024) for Medicaid and Medicare members in the measurement year or two years prior (2022–2024) for commercial members <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>Initiation and Engagement of Substance Use Disorder Treatment (IET)</p> <p>Ages 13 and older</p> <p>Codes To Identify AOD Visits: 98960–98962, 99078, 99205, 99211–99215, 99241–99245, 99341–99345, 99347–99350, 99384–99387, 99394–99397, 99401–99404, 99408–99409, 99411–99412, 99483, 99510</p>	<p>New substance use disorder (SUD) episodes (194 days negative diagnosis history) that results in treatment initiation and engagement.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> initiation of SUD treatment within 14 days of the diagnosis through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, or partial hospitalization, telehealth, or medication treatment engagement of SUD treatment evidence of treatment engagement within 34 days of the initiation <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>*Prenatal/Postpartum Care (PPC)</p> <p>Members who delivered a live infant between October 8, 2023, and October 7, 2024</p> <p>Codes To Identify Timeliness of Prenatal Care CPT: 99205, 99211–99215, 99241–99245, 99483</p> <p>Postpartum Care CPT: 57170, 58300, 59430, 99501</p>	<p>Two components to assess prenatal and postpartum care:</p> <ol style="list-style-type: none"> timeliness of prenatal care – received a prenatal care visit in the first trimester, on or before the enrollment start date, or within 42 days of enrollment postpartum care – had a postpartum visit on or between 7 and 84 days after delivery <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)
 For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Use of First-line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)*</p> <p>Ages 1–17 years</p> <p>CPT Codes To Identify Psychosocial Care: 90832–90834, 90836–90840, 90845–90847, 90849, 90853, 90875–90876, 90880</p> <p>*Developed with financial support from the Agency for Healthcare Research and Quality (AHRQ) and CMS under the CHIPRA Pediatric Quality Measures Program Centers of Excellence grant number U18HS020503, from a measure developed by MedNet Medical Solutions.</p>	<p>Members who had a new prescription (4-month negative medication history) for an antipsychotic medication and had documentation of psychosocial care as first-line treatment during the period from 90 days prior to 30 days after the prescription fill</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members for whom first-line antipsychotic medications may be clinically appropriate: members with a diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism, or other developmental disorder on at least two different dates of service during the measurement year (2024) members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)
 For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Utilization and Risk-adjusted Utilization

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Well-child Visits in the First 30 months of Life (W30)</p> <p>Children who turned 15 months or 30 months during measurement year 2024</p> <p>CPT Codes To Identify Well-child Visits: 99381–99385</p>	<p>Well-child visits with a PCP/pediatrician during the last 15 months</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> six (6) or more well-child visits on different dates of service on or before the 15-month birthday two (2) or more well-child visits on different dates of service between the child's 15-month birthday plus one day and the 30-month birthday <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>Child and Adolescent Well-care Visits (WCV)</p> <p>Ages 3–21 years</p> <p>CPT Codes To Identify Well-child Visits 99381–99385, 99391–99395, 99461</p> <p>ICD-10 Codes: Z00.00–Z00.01, Z00.110–Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z00.5, Z76.1–Z76.2</p>	<p>At least one (1) comprehensive well-care visit with a PCP or OB/GYN practitioner during the measurement year (2024)</p> <p>The well-care visit must occur with a PCP or an OB/GYN practitioner.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died anytime during the measurement year
<p>Antibiotic Utilization for Respiratory Conditions (AXR)</p> <p>Ages 3 months and older</p>	<p>Diagnosis of a respiratory condition that resulted in a prescription for an antibiotic medication (AXR) on or three days after the episode from July 1, 2023–June 30, 2024</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services during the measurement year members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Breast Cancer Screening (BCS-E)</p> <p>Women ages 50–74</p>	<p>A mammogram to screen for breast cancer on or between October 1, 2022–December 31, 2024</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services or receiving palliative care anytime during the measurement year bilateral mastectomy anytime during the member’s history through the end of the measurement year members who died anytime during the measurement year
<p>Cervical Cancer Screening (CCS-E)</p>	<ul style="list-style-type: none"> a PAP test (cervical cytology) within the last three years (2022–2024) for members ages 21–64 cervical high-risk human papillomavirus (hrHPV) testing within the last five years (2020–2024) for members ages 30–64. cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last five years (2020–2024) for members ages 30–64. <p>Documentation in the record must include both of the following:</p> <ul style="list-style-type: none"> date the test was performed result or finding <p>Exclusions:</p> <ul style="list-style-type: none"> documentation of hysterectomy with <i>no residual cervix, cervical agenesis, or acquired absence of cervix</i> members in hospice or using hospice services or receiving palliative care anytime during the measurement year members who died anytime during the measurement year
<p>Colorectal Cancer Screening (COL-E)</p> <p>Adults ages 45–75</p>	<p>One or more of the following screenings:</p> <ul style="list-style-type: none"> fecal occult blood test (iFOBT or gFOBT) annually in the measurement year (2024) flexible sigmoidoscopy in the past five years (2020–2024) colonoscopy in past 10 years (2015–2024) CT colonography (e.g., virtual colonoscopy) in the past five years (2020–2024) FIT-DNA (e.g., Cologuard) test in the past three years (2022–2024) <p>Exclusions:</p> <ul style="list-style-type: none"> diagnosis of colorectal cancer or total colectomy any time during the member’s history through the measurement year members in hospice or using hospice services or receiving palliative care anytime during the measurement year members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Childhood Immunization Status (CIS-E)</p> <p>Children who turn 2 years old during the measurement year</p> <p><i>Note: Vaccines must be completed on or before the second birthday.</i></p> <p>Parental refusal is <i>not</i> an exclusion</p>	<ul style="list-style-type: none"> • 4 DTaP or anaphylaxis or encephalitis due to diphtheria, tetanus, or pertussis vaccine (do not count any before 42 days of age) • 3 IPV or anaphylaxis due to the IPV vaccine (do not count any before 42 days of age) • 1 MMR; history of measles, mumps, and rubella; or anaphylaxis due to the MMR vaccine (do not count any before 42 days of age) • 3 HiB or anaphylaxis due to HiB vaccine (do not count any before 42 days of age) • 3 hepatitis B, anaphylaxis due to hepatitis B vaccine, positive serology, or history of hepatitis B • 1 VZV, anaphylaxis due to the VZV vaccine, positive serology, or documented history of chicken pox disease • 4 pneumococcal conjugates or anaphylaxis due to the pneumococcal conjugate vaccine (do not count any before 42 days of age) • 1 hepatitis A, anaphylaxis due to the hepatitis A vaccine, or documented hepatitis A illness • 2 or 3 rotavirus vaccines – depends on the vaccine administered or documented anaphylaxis due to the rotavirus vaccine (do not count any before 42 days of age) • 2 influenza with different dates of service or anaphylaxis due to the influenza vaccine <ul style="list-style-type: none"> – One of the two vaccinations can be a live attenuated influenza vaccine (LAIV) if administered on the child’s second birthday (do not count any given prior to 6 months of age). <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who had a contraindication to a childhood vaccine on or before their second birthday • members who died anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)
 For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Immunizations for Adolescents (IMA-E)</p> <p>Adolescents who turn 13 years old in 2024</p> <p><i>All vaccines must be completed on or before 13th birthday.</i></p> <p><i>Note: This measure includes the human papillomavirus vaccine (HPV) for both males and females.</i></p> <p>Parental refusal is <i>not</i> an exclusion</p>	<ul style="list-style-type: none"> • 1 dose meningococcal vaccine between the 11th and 13th birthdays or anaphylaxis due to the vaccine anytime on or before the member's 13th birthday and • 1 tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine between the 10th and 13th birthdays or anaphylaxis or encephalitis due to the vaccine anytime on or before the 13th birthday and • 2-dose or 3-dose HPV vaccination series between the 9th and 13th birthdays or anaphylaxis due to the vaccine anytime on or before the 13th birthday <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members who died anytime during the measurement year
<p>Follow-up Care for Children Prescribed ADHD Medication (ADD-E)</p> <p>Ages 6–12</p>	<p>Members with a newly prescribed ADHD medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was prescribed.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. Initiation Phase: one follow-up visit with a prescribing practitioner with prescribing authority within 30 days 2. Continuation and Maintenance Phase: remained on the medication for at least 210 days and had two additional visits with a practitioner within 270 days (9 months) after the Initiation Phase ended. <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice services anytime during the measurement year • members with a diagnosis of narcolepsy anytime during their history through the measurement year • members who died during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E) *</p> <p>Ages 1-17</p> <p><small>*Developed with financial support from the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare & Medicaid Services (CMS) under the CHIPRA Pediatric Quality Measures Program Centers of Excellence grant number U18 HS020503.</small></p>	<p>Children and adolescents who had two or more antipsychotics prescriptions and had metabolic testing</p> <p>Three rates are reported:</p> <ol style="list-style-type: none"> children and adolescents on antipsychotics who received blood glucose testing children and adolescents on antipsychotics who received cholesterol testing children and adolescents on antipsychotics who received blood glucose and cholesterol testing <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died during the measurement year
<p>Unhealthy Alcohol Use Screening and Follow-up (ASF-E)</p> <p>Adults ages 18 and older</p>	<ul style="list-style-type: none"> screened for unhealthy alcohol use using a standardized tool (AUDIT, Single-question Screen) <p>and</p> <ul style="list-style-type: none"> if screened positive, received brief counseling or other follow-up care within two months (e.g., feedback on alcohol use and harms, identification of high-risk situations for drinking and coping strategies, development of a personal plan to reduce drinking, documentation of receiving alcohol misuse treatment) <p>Exclusions:</p> <ul style="list-style-type: none"> members with alcohol use disorder that starts during the year prior to the measurement year members with a history of dementia anytime during the member’s history through the end of the measurement year members in hospice or using hospice services anytime during the measurement year members who died during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Depression Screening and Follow-up for Adolescents and Adults (DSF-E)</p> <p>Ages 12 years and older</p>	<p>Screened for clinical depression using a standardized tool and, if screened positive, received follow-up care within 30 days (e.g., an outpatient or telephone follow-up visit, a depression case management encounter, a behavioral health encounter, dispensed antidepressant medication) of a positive depression screen finding</p> <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year (2024) members with a history of bipolar disorder anytime during the member’s history through the end of the year prior to the measurement year (2023) members with depression that starts in the prior year (2023) through the measurement year (2024) members who died during the measurement year
<p>Depression Remission or Response for Adolescents and Adults (DRR-E)</p> <p>Ages 12 and older</p>	<p>Diagnosis of major depression with an elevated PHQ-9 (total score ≥ 9) or dysthymia who had evidence of response or remission within four to eight months of the elevated score.</p> <p>Three rates are reported:</p> <ol style="list-style-type: none"> Follow-up PHQ-9 within four to eight months after the initial elevated PHQ-9 score Depression Remission: achieved remission within four to eight months after the initial elevated PHQ-9 score of <5 Depression Response: showed a response within four to eight months after the initial elevated PHQ-9 score with PHQ-9 score reduction of at least 50% <p>Exclusions:</p> <ul style="list-style-type: none"> members with any of the following anytime during the member’s history through the end of the measurement year: bipolar disorder, personality disorder, psychotic disorder, or pervasive developmental disorder members in hospice or using hospice services anytime during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Utilization of the PHQ-9 To Monitor Depression Symptoms for Adolescents and Adults (DMS-E)</p> <p>Ages 12 and older</p>	<p>Diagnosis of major depression or dysthymia and had an outpatient encounter with a PHQ-9 score present in their record in the same assessment period as the encounter.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> Inclusion in ECDS Rate: The percentage of members 12 and older with a diagnosis of major depression or dysthymia, who are included in an electronic clinical data system (ECDS). Utilization of PHQ-9 Rate: The percentage of PHQ utilization. Members with a diagnosis of major depression or dysthymia who are covered by an ECDS and, if they had an outpatient encounter, have a PHQ-9 score present in their record. <p>Exclusions:</p> <ul style="list-style-type: none"> members with any of the following anytime during the member’s history through the end of the measurement year: bipolar disorder, personality disorder, psychotic disorder, or pervasive developmental disorder members in hospice or using hospice services anytime during the measurement year members who died during the measurement year
<p>Adult Immunization Status (AIS-E)</p> <p>Adults ages 19 and older</p>	<p>Received recommended routine vaccines:</p> <ul style="list-style-type: none"> influenza vaccine on or between July 1, 2023–June 30, 2024, or members with anaphylaxis due to influenza anytime before or during the measurement year Td or Tdap on or between January 1, 2015–December 31, 2024, or members with a history of anaphylaxis or encephalitis due to diphtheria, tetanus, or pertussis vaccine zoster (one dose of herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine, at least 28 days apart anytime on or after the member’s 50th birthday and before or during 2024 or had anaphylaxis due to herpes zoster vaccine anytime before or during 2024 pneumococcal vaccine on or after the member’s 19th birthday or had anaphylaxis due to pneumococcal vaccine <p>Exclusions:</p> <ul style="list-style-type: none"> members in hospice or using hospice services anytime during the measurement year members who died during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Prenatal Immunization Status (PRS-E)</p> <p>Deliveries in the measurement year (2024)</p>	<p>Received the following recommended vaccines during the measurement year (2024):</p> <ul style="list-style-type: none"> • influenza • tetanus, diphtheria toxoids, and acellular pertussis (Tdap) during the pregnancy (including on the delivery date) <p>Exclusions:</p> <ul style="list-style-type: none"> • deliveries in which members were in hospice or using hospice services anytime during the measurement period • deliveries that occurred at less than 37 weeks gestation • members who died during the measurement year
<p>Prenatal Depression Screening and Follow-up (PND-E)</p>	<p>Screened for clinical depression while pregnant and, if screening is positive, received follow-up care.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. Depression Screening: screened for clinical depression during pregnancy using a standardized instrument. 2. Follow-up on Positive Screen: received follow-up care within 30 days of a positive depression screening finding. <p>Exclusions:</p> <ul style="list-style-type: none"> • deliveries in which members were in hospice or using hospice services anytime during the measurement period • deliveries that occurred at less than 37 weeks gestation • members who died during the measurement year
<p>Postpartum Depression Screening and Follow-up (PDS-E)</p> <p>Adults ages 45–75</p>	<p>Screened for clinical depression during the postpartum period and, if screened positive, received follow-up care.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> 1. Depression Screening: screened for clinical depression using a standardized instrument during the postpartum period (7–84 days following date of delivery). 2. Follow-up on Positive Screen: received follow-up care within 30 days of a positive depression screen finding. <p>Exclusions:</p> <ul style="list-style-type: none"> • deliveries in which members were in hospice or using hospice services anytime during the measurement period • members who died during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015

Measures Collected Through Electronic Clinical Data Systems (ECDS)

HEDIS¹
MY 2024

MEASURE	SCREENING, TEST, OR CARE NEEDED
<p>Social Need Screening and Intervention (SNS-E)</p> <p>Ages: ≤ 17-65 years</p>	<p>Members who were screened, using prespecified instruments, at least once during the measurement year (2024) for unmet food, housing, and transportation needs, and received a corresponding intervention within one month if they screened positive</p> <p>Interventions may include any of the following intervention categories: assistance, assessment, counseling, coordination, education, evaluation of eligibility, provision, or referral.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> • members in hospice or using hospice during the measurement year • Medicare members 66 years of age and older by the end of the measurement year who meet either of the following: <ul style="list-style-type: none"> • enrolled in an Institutional SNP (I-SNP) during the measurement year • living long-term in an institution during the measurement year, as identified by the LTI flag in the monthly membership detail data file • members who died during the measurement year

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2024, please contact the quality improvement department at 757-252-8400 or toll-free at 1-844-620-1015